Skip to content
10-Q

Quarterly Report

CHINA PHARMA HOLDINGS, INC. CPHI

0001213900-24-068984

← back to feed
Filed
Aug 14, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Aug 12, 2024 17.16M sh
Current Liabilities Q2 2024 · Jun 30, 2024 $4.71M
Current Liabilities Q2 2024 · Dec 31, 2023 $6.82M
Total Liabilities Q2 2024 · Jun 30, 2024 $6.85M
Total Liabilities Q2 2024 · Dec 31, 2023 $9.01M
Current Assets Q2 2024 · Jun 30, 2024 $3.97M
Current Assets Q2 2024 · Dec 31, 2023 $6M
Total Assets Q2 2024 · Jun 30, 2024 $14.26M
Total Assets Q2 2024 · Dec 31, 2023 $16.47M
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$1.68M
Stockholders Equity Q2 2024 · Jun 30, 2023 $4.35M
Stockholders Equity Q2 2024 · Mar 31, 2023 $4.67M
Stockholders Equity Q2 2024 · Dec 31, 2022 $4.29M
Eps Diluted restated Q2 2024 · Jun 30, 2023 −$0.35
Eps Diluted restated Q2 2024 · Jun 30, 2023 −$0.65
Eps Basic restated Q2 2024 · Jun 30, 2023 −$0.35
Eps Basic restated Q2 2024 · Jun 30, 2023 −$0.65
Sga Expense Q2 2024 · Jun 30, 2023 $112.03K
Sga Expense Q2 2024 · Jun 30, 2023 $530.03K
Rd Expense Q2 2024 · Jun 30, 2023 $23.75K
Rd Expense Q2 2024 · Jun 30, 2023 $46.76K
Net Income Q2 2024 · Jun 30, 2023 −$593.03K
Net Income Q2 2024 · Jun 30, 2023 −$1.07M
Net Income Q2 2024 · Mar 31, 2023 −$475.98K
Operating Income Q2 2024 · Jun 30, 2023 −$456.31K
Operating Income Q2 2024 · Jun 30, 2023 −$853.79K
Gross Profit Q2 2024 · Jun 30, 2023 −$146.66K
Gross Profit Q2 2024 · Jun 30, 2023 $31.26K
Cost Of Revenue Q2 2024 · Jun 30, 2023 $1.24M
Cost Of Revenue Q2 2024 · Jun 30, 2023 $3.03M
Revenue Q2 2024 · Jun 30, 2023 $1.1M
Revenue Q2 2024 · Jun 30, 2023 $3.06M